AirLogix is the most experienced and trusted leader in chronic respiratory management. Through compassion and dedication, the AirLogix team has delivered the most effective, patient-centric Asthma and COPD programs to over 400,000 members. Through their specialization in respiratory management, AirLogix uses self-care therapies, in-home interaction, and powerful informatics processes to deliver the most effective clinical results, higher patient/provider satisfaction and greater ROI/cost reductions in respiratory management. For more information, please visit www.AirLogix.com.

McKesson's CareEnhance® Disease Management Services provide market-leading, integrated telephonic and community-based programs to Medicaid and Medicare beneficiaries living with asthma, diabetes, heart failure, COPD, CAD, schizophrenia and chronic pain. We manage millions of Medicaid and Medicare beneficiaries while demonstrating the ability to coordinate partnerships and integrate with existing State and/or health plan programs and resources. Our guaranteed risk approach helps reduce unnecessary healthcare costs while improving the health and quality of life of underserved and needy populations. McKesson was recently chosen by the Centers for Medicare and Medicaid Services (CMS) to lead a Chronic Care Improvement Program pilot in the state of Mississippi. www.healthsolutions.mckesson.com

XLHealth, (www.xlhealth.com) is a pioneer in its disease management approach -- replacing the more customary remote telephone “call-center” or direct mail support with ongoing, face-to-face meetings with patients and physicians. XLHealth also uses tight coordination of care, behavior modification, and in-depth patient profiling integrated with claims, pharmacy, and lab information to generate sophisticated, predictive modeling. The firm emphasizes preventing avoidable and expensive disease complications and hospitalizations. A recognized leader in disease management and support, XLHealth was named one of the “Top Ten Disease Management Companies in America” by the U.S. Health Industry Research Council for the past three years.